Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14148998 | 0.76 | KDM4E (0.59) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL3470444 | 0.75 | KDM4E (0.58) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL6183937 | 0.74 | KDM4E (0.53) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL28874875 | 0.73 | KDM4E (0.52) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL12501247 | 0.71 | LMNA (0.54) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL4099271 | 0.70 | KDM4E (0.66) | ALDH1A1KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL4099273 | 0.70 | KDM4E (0.66) | ALDH1A1KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL119513 | 0.69 | ALDH1A1 (0.61) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL12501245 | 0.68 | LMNA (0.51) | ALDH1A1KDM4EMAPTSTAT3KMT2A | |
| SCHEMBL15450912 | 0.68 | ALDH1A1 (0.60) | ALDH1A1KDM4EKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210215670-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2021-07-15 | — | — | US | disclosed |
| US-20210215671-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2021-07-15 | — | — | US | disclosed |
| US-10955408-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200049693-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2020-02-13 | — | — | US | disclosed |
| US-10018619-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-9795610-B2 | Theramutein modulators | Housey, Gerard M. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9645137-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2017-05-09 | — | — | US | disclosed |
| US-9579326-B2 | Theramutein modulators | HMI Medical Innovations, LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150133441-A1 | THERAMUTEIN MODULATORS | HMI MEDICAL INNOVATIONS, LLC. | 2015-05-14 | — | — | US | disclosed |
| US-8431110-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI MEDICAL INNOVATIONS, LLC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8367038-B2 | Blocking or activation of endogenous proteins variations rncoded by mutated gees | HMI Medical Innovations, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2447252-A2 | Theramutein modulators | Housey, Gerard M. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20080269262-A1 | Blocking or activation of endogenous proteins variations rncoded by mutated gees | HMI MEDICAL INNOVATIONS, LLC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133441-A1 | THERAMUTEIN MODULATORS | TSG101, SERPINE1, PLAUR | ALDH1A1 4411/4885KDM4E 4221/4885MAPT 2984/4885 |
| US-20080269262-A1 | Blocking or activation of endogenous proteins variations rncoded by mutated gees | SERBP1, SERPINA6, UBE2V1 | ALDH1A1 3621/4885KDM4E 4172/4885MAPT 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.